Method | Sensitivity 95% CI | Specificity 95% CI | PPVa 95% CI | NPV 95% CI |
---|---|---|---|---|
Culture | 8.4% (13/155) | 100.0% (64/64) | 100.0% (13/13) | 31.1% (64/206) |
(4.0–12.8%) | (92.9–100.0%) | (100.0–100.0%) | (24.7–37.4%) | |
GeneXpert | 14.2% (22/155) | 100.0% (64/64) | 100.0% (22/22) | 32.5% (64/197) |
(8.7–19.7%) | (92.9–100.0%) | (100.0–100.0%) | (25.9–39.0%) | |
LAM | 35.5% (55/155) | 96.9% (62/64) | 96.5% (55/57) | 38.3% (62/162) |
 | (28.1–43.6%) | (88.2–99.5%) | (91.7–100.0%) | (30.8–45.8%) |
Culture+GeneXpert | 14.8% (23/155) | 100.0% (64/64) | 100.0% (23/23) | 32.7% (64/196) |
(9.2–20.4%) | (92.9–100.0%) | (100.0–100.0%) | (26.1–39.2%) | |
Culture+LAM | 38.7% (60/155) | 96.9% (62/64) | 96.8% (60/62) | 39.5% (62/157) |
(31.0–46.4%) | (88.2–99.5%) | (92.4–100.0%) | (31.8–47.1%) | |
GeneXpert+LAM | 40.0% (62/155) | 96.9% (62/64) | 96.9% (62/64) | 40.0% (62/155) |
(32.3–47.7%) | (88.2–99.5%) | (92.6–100.0%) | (32.3–47.7%) | |
Culture+GeneXpert+LAM | 40.6% (63/155) | 96.9% (62/64) | 96.9% (63/65) | 40.3% (62/154) |
(32.9–48.4%) | (88.2–99.5%) | (92.7–100.0%) | (32.5–48.0%) |